Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Chris Cheadle PhD

Chris Cheadle PhD

Director of Genomics, R&D Research

Connect with Chris Cheadle PhD on LinkedIn

About the author: Dr. Chris Cheadle is the Director of Research for Biology Products, Elsevier Life Sciences. He trained in Molecular Biology began and earned a doctorate in Genetics from George Washington University, followed by a postdoctoral fellowship at the National Institute of Aging in the Microarray Core. He served as Director of the Lowe Family Genomics Core at the Johns Hopkins University from 2005-15. In his role at Elsevier, Chris has been responsible for helping to formulate the vision of the New Biology Strategy (NBS) expected to guide development for new products and make more effective use of present day assets in the future.

Posts by Chris Cheadle PhD

Modeling Coronavirus – Cytokine Storm

Posted on September 4th, 2020 in COVID-19

Figure 1. Classification of COVID-19 Disease States.
Adapted from Sidiqi, H.K. and M.R. Mehra, COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant, 2020. [1]

(This piece was co-authored by Prof. Gordon Broderick, Clinical Systems Biology at Rochester General Hospital.)

The thing that kills you with coronavirus is not necessarily the infection itself but rather your own body’s response to the infection. Failure to clear the virus with an appropriate immune response can lead to pulmonary symptoms of increasing severity and which can even be fatal in a minority of cases (Figure 1). This late stage of a COVID-19 infection is characterized by a state of hyperinflammation or, as it is more commonly known, a “cytokine storm”.


Analgesics Use and the Coronavirus: Finding Answers Through Biological Knowledge Graph

Posted on March 31st, 2020 in COVID-19

a. 121 ARDS-induced proteins whose activity and/or abundance are upregulated by ARDS

Collaboration Drives an Exciting Development for In Silico Disease Modeling

Posted on April 9th, 2019 in Pharma R&D

Partnerships between organizations with complementary goals and capabilities are increasingly proving to pave paths towards revolutionary advancements in life sciences. One such partnership is highlighted between Elsevier and Rochester General Hospital at ConTech 2018 in the field of In Silico Disease Modelling.